Atara Biotherapeutics To Present Preclinical Data On ATA3219, An Allogeneic CD19-Targeted CAR T Therapy For The Treatment Of B-Cell Driven Autoimmune Diseases, At The ISCT 2024 Annual Meeting

5/29/24 4:02:12 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ATRA alert in real time by email

ATA3219 Demonstrates Complete CD19-Specific B-Cell Depletion Against Systemic Lupus Erythematosus and Multiple Sclerosis Patient Peripheral Blood Mononuclear Cells

ATA3219 Induces Lower Levels of Pro-Inflammatory Cytokines While Maintaining Cytotoxic Potency Compared With Autologous Benchmark CD19 CAR T Cells

Results Support Clinical Evaluation of ATA3219, Including Initiation of Phase 1 Study in Lupus Nephritis and Severe Systemic Lupus Erythematosus Without Lymphodepletion Expected in Q4 2024

Get the next $ATRA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ATRA

Date	Price Target	Rating	Analyst
11/9/2023		Outperform → In-line	Evercore ISI
11/9/2023		Buy → Neutral	H.C. Wainwright
11/9/2023	$31.00 → $1.00	Buy → Neutral	Mizuho
7/20/2022	$8.00 → $3.00	Neutral → Sell	Citigroup
7/13/2022	$10.00	Overweight → Neutral	JP Morgan
7/13/2022	$16.00 → $5.00	Buy → Hold	Stifel
5/10/2022	$15.00 → $8.00	Buy → Neutral	Citigroup
1/3/2022	$26.00 → $27.00	Overweight	JP Morgan

More analyst ratings

$ATRA
Press Releases

Fastest customizable press release news feed in the world

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 6:10 a.m. PST / 9:10 a.m. EST. A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation. Ab
11/13/24 4:01:00 PM ET
$ATRA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
Tab-cel® U.S. BLA On-Track With PDUFA Target Action Date of January 15, 2025 First Patient Dosed for ATA3219 Non-Hodgkin's Lymphoma Study; Initial Clinical Data Expected Q1 2025 ATA3219 Lupus Nephritis and Extrarenal Systemic Lupus Erythematosus Study Initiation Expected by End of Year; Initial Clinical Data Expected Mid-2025 Cash Runway Into 2027 Enables Key Pipeline Readouts Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2024, recent busines
11/12/24 4:01:00 PM ET
$ATRA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2024 financial results after market close on Tuesday, Nov 12, 2024. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the w
11/5/24 4:01:00 PM ET
$ATRA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2024 financial results after market close on Tuesday, Nov 12, 2024. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the w
11/5/24 4:01:00 PM ET
$ATRA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel®, including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining Markets Atara to Receive Additional Payments of up to USD 640 Million, Significant Double-digit Tiered Royalties as a Percentage of Net Sales, and Funding of Tab-cel Global Development Costs Tab-cel Global Partnership and Associated Strategic Restructuring Extends Atara Cash Runway into Q3 2025 ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication on Track for Early November Atara to Host Conference Call and Webcast today at 6:00 a.m. PDT / 9:00 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA),
11/1/23 8:30:00 AM ET
$ATRA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2023 financial results after market close on Tuesday, August 8, 2023. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, At
8/1/23 4:01:00 PM ET
$ATRA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Atara Biotherapeutics To Present Preclinical Data On ATA3219, An Allogeneic CD19-Targeted CAR T Therapy For The Treatment Of B-Cell Driven Autoimmune Diseases, At The ISCT 2024 Annual Meeting

Chat with this insight

Recent Analyst Ratings for $ATRA

$ATRA Press Releases

Fastest customizable press release news feed in the world

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

$ATRA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Atara Biotherapeutics downgraded by Evercore ISI

Atara Biotherapeutics downgraded by H.C. Wainwright

Atara Biotherapeutics downgraded by Mizuho with a new price target

$ATRA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, Chief Regulatory Officer Henrich Jill sold $11,198 worth of shares (1,000 units at $11.20), decreasing direct ownership by 5% to 19,378 units (SEC Form 4)

EVP, CFO and COO Hyllengren Eric J sold $15,274 worth of shares (1,364 units at $11.20), decreasing direct ownership by 6% to 23,392 units (SEC Form 4)

President and CEO Nguyen Anhco sold $18,633 worth of shares (1,664 units at $11.20), decreasing direct ownership by 2% to 77,454 units (SEC Form 4)

$ATRA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Gallagher Carol Giltner bought $68,214 worth of shares (270,000 units at $0.25), increasing direct ownership by 143% to 459,418 units (SEC Form 4)

Dobmeier Eric bought $101,340 worth of shares (446,825 units at $0.23), increasing direct ownership by 384% to 563,325 units (SEC Form 4)

Heiden William K bought $25,330 worth of shares (100,000 units at $0.25), increasing direct ownership by 92% to 209,000 units (SEC Form 4)

$ATRA Financials

Live finance-specific insights

$ATRA Market Insights

Live Market Insights

$ATRA Leadership Updates

Live Leadership Updates

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results

Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $11

Atara Biotherapeutics Receives FDA Acceptance And Priority Review Of Biologics License Application For Tabelecleucel For Treatment Of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors

$ATRA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

$ATRA SEC Filings

SEC Form 10-Q filed by Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

SEC Form 8-K filed by Atara Biotherapeutics Inc.

Recent Analyst Ratings for
$ATRA

$ATRA
Press Releases

$ATRA
Analyst Ratings

$ATRA
Insider Trading

$ATRA
Insider Purchases

$ATRA
Financials

$ATRA
Market Insights

$ATRA
Leadership Updates

$ATRA
Large Ownership Changes

$ATRA
SEC Filings